Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019 · New England Journal of Medicine · 3,642 citations
https://doi.org/10.1056/nejmoa1910836
P
Patrick Schöffski
KU Leuven(BE)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.1K
Papers
43.5K
Citations
93
h-index
371
i10-index
Patrick Schöffski is an academic researcher from KU Leuven. The author has contributed to research in topics: Gastrointestinal Tumor Research and Treatment & Sarcoma Diagnosis and Treatment & Gastric Cancer Management and Outcomes. The author has an h-index of 93, co-authored 961 publications.
ORCID: 0000-0001-5980-030XPapers by this author
worksSoft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 · Annals of Oncology · 1,598 citations
https://doi.org/10.1093/annonc/mdy096
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 · The Lancet · 1,392 citations
https://doi.org/10.1016/s0140-6736(12)61857-1
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 · Annals of Oncology · 623 citations
https://doi.org/10.1093/annonc/mdy310
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
2021 · Annals of Oncology · 524 citations
https://doi.org/10.1016/j.annonc.2021.09.005
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
2024 · New England Journal of Medicine · 378 citations
https://doi.org/10.1056/nejmoa2407417
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat